UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Dancing partners at the ball: Rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era

Blood reviews, 2017-09, Vol.31 (5), p.318-327

2017

Volltextzugriff (PDF)

Therapeutic potential of AAV-mediated MMP-3 secretion from corneal endothelium in treating glaucoma

Human molecular genetics, 2017-04, Vol.26 (7), p.1230-1246

2017

Volltextzugriff (PDF)

Prevention of autosomal dominant retinitis pigmentosa by systemic drug therapy targeting heat shock protein 90 (Hsp90)

Human molecular genetics, 2010-11, Vol.19 (22), p.4421-4436

2010

Volltextzugriff (PDF)

Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies

American journal of hematology, 2004-09, Vol.77 (1), p.72-76

2004

Volltextzugriff (PDF)

Therapeutic benefit derived from RNAi-mediated ablation of IMPDH1 transcripts in a murine model of autosomal dominant retinitis pigmentosa (RP10)

Human molecular genetics, 2008-07, Vol.17 (14), p.2084-2100

2008

Volltextzugriff (PDF)

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

The New England journal of medicine, 2014-07, Vol.371 (3), p.213-223

2014

Volltextzugriff (PDF)

Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation

Leukemia, 2015-04, Vol.29 (4), p.783-787

2015

Volltextzugriff (PDF)

experimental platform for systemic drug delivery to the retina

Proceedings of the National Academy of Sciences - PNAS, 2009-10, Vol.106 (42), p.17817-17822

2009

Volltextzugriff (PDF)

330MO Pooled safety analysis of zanubrutinib monotherapy in Asian patients with B cell malignancies

Annals of oncology, 2023-11, Vol.34, p.S1599-S1600

2023

Volltextzugriff (PDF)

Housing price gradient with two workplaces — An empirical study in Hong Kong

Regional science and urban economics, 2007-05, Vol.37 (3), p.413-429

2007

Volltextzugriff (PDF)

Choosing and sequencing novel drugs in CLL: dealing with an embarrassment of riches?

Annals of oncology, 2017-05, Vol.28 (5), p.920-921

2017

Volltextzugriff (PDF)

Obesity and low-grade inflammation: a paediatric perspective

Obesity reviews, 2010-02, Vol.11 (2), p.118-126

2010

Volltextzugriff (PDF)

ZANUBRUTINIB PLUS OBINUTUZUMAB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

Hematological oncology, 2019-06, Vol.37 (S2), p.121-122

2019

Volltextzugriff (PDF)

Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy

Leukemia, 2010-12, Vol.24 (12), p.2056-2062

2010

Volltextzugriff (PDF)

Preclinical evaluation of FLT190, a liver-directed AAV gene therapy for Fabry disease

Gene therapy, 2023-06, Vol.30 (6), p.487-502

2023

Volltextzugriff (PDF)

Gene targeting as a therapeutic avenue in diseases mediated by the complement alternative pathway

Immunological reviews, 2023-01, Vol.313 (1), p.402-419

2023

Volltextzugriff (PDF)

Soft drink consumption and excess weight gain in Australian school students: results from the Nepean study

International Journal of Obesity, 2006-07, Vol.30 (7), p.1091-1093

2006

Volltextzugriff (PDF)

Erect bipedal stance exercise partially prevents orchidectomy-induced bone loss in the lumbar vertebrae of rats

Bone, 2000-11, Vol.27 (5), p.667-675

2000

Volltextzugriff (PDF)

AN UNDETECTABLE PB MRD STATUS SHOULD BE THE THERAPEUTIC GOAL WITH VENETOCLAX THERAPY IN RELAPSED/ REFRACTORY CLL

Hematological oncology, 2019-06, Vol.37 (S2), p.108-109

2019

Volltextzugriff (PDF)

ZANUBRUTINIB PLUS OBINUTUZUMAB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

Hematological oncology, 2019-06, Vol.37 (S2), p.121-122

2019

Volltextzugriff (PDF)

AN IMPROVED BENEFIT‐RISK PROFILE OF DUVELISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA WHO RECEIVED 2 OR MORE PRIOR THERAPIES

Hematological oncology, 2019-06, Vol.37 (S2), p.213-214

2019

Volltextzugriff (PDF)

UPDATED SAFETY AND EFFICACY DATA IN THE PHASE 1 TRIAL OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) TREATED WITH BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB‐3111)

Hematological oncology, 2019-06, Vol.37 (S2), p.245-247

2019

Volltextzugriff (PDF)

EFFECT OF DOSE MODIFICATIONS ON RESPONSE TO DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY CLL/SLL IN THE DUO TRIAL

Hematological oncology, 2019-06, Vol.37 (S2), p.214-216

2019

Volltextzugriff (PDF)

Age-related changes in eye morphology and aqueous humor dynamics in DBA/2J mice using contrast-enhanced ocular MRI

Magnetic resonance imaging, 2019-06, Vol.59, p.10-16

2019

Volltextzugriff (PDF)

A HEAD‐TO‐HEAD PHASE 3 STUDY COMPARING BGB‐3111 AND IBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA

Hematological oncology, 2017-06, Vol.35 (S2), p.422-423

2017

Volltextzugriff (PDF)

1 – 25 von 184

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(172)
Mit Volltextzugriff
(158)

Publikationsform

Sprache

Englisch
(184)

Erscheinungsjahr

n.n

Thema

Science & Technology
(118)
Life Sciences & Biomedicine
(108)
Humans
(89)
Male
(52)
Female
(50)
Middle Aged
(40)
Aged
(37)
Biological And Medical Sciences
(34)
Adult
(31)
Medical Sciences
(28)
Animals
(22)
Cohort Studies
(19)
Patients
(17)
Aged, 80 And Over
(16)
Fundamental And Applied Biological Sciences. Psychology
(15)
Cardiovascular System & Cardiology
(14)
Genetics & Heredity
(14)
Risk Factors
(14)
Chronic Lymphocytic Leukemia
(12)
Cardiovascular
(11)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Dancing partners at the ball: Rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era

Therapeutic potential of AAV-mediated MMP-3 secretion from corneal endothelium in treating glaucoma

Prevention of autosomal dominant retinitis pigmentosa by systemic drug therapy targeting heat shock protein 90 (Hsp90)

Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies

Therapeutic benefit derived from RNAi-mediated ablation of IMPDH1 transcripts in a murine model of autosomal dominant retinitis pigmentosa (RP10)

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation

experimental platform for systemic drug delivery to the retina

330MO Pooled safety analysis of zanubrutinib monotherapy in Asian patients with B cell malignancies

Housing price gradient with two workplaces — An empirical study in Hong Kong

Choosing and sequencing novel drugs in CLL: dealing with an embarrassment of riches?

Obesity and low-grade inflammation: a paediatric perspective

ZANUBRUTINIB PLUS OBINUTUZUMAB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy

Preclinical evaluation of FLT190, a liver-directed AAV gene therapy for Fabry disease

Gene targeting as a therapeutic avenue in diseases mediated by the complement alternative pathway

Soft drink consumption and excess weight gain in Australian school students: results from the Nepean study

Erect bipedal stance exercise partially prevents orchidectomy-induced bone loss in the lumbar vertebrae of rats

AN UNDETECTABLE PB MRD STATUS SHOULD BE THE THERAPEUTIC GOAL WITH VENETOCLAX THERAPY IN RELAPSED/ REFRACTORY CLL

ZANUBRUTINIB PLUS OBINUTUZUMAB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

AN IMPROVED BENEFIT‐RISK PROFILE OF DUVELISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA WHO RECEIVED 2 OR MORE PRIOR THERAPIES

UPDATED SAFETY AND EFFICACY DATA IN THE PHASE 1 TRIAL OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) TREATED WITH BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB‐3111)

EFFECT OF DOSE MODIFICATIONS ON RESPONSE TO DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY CLL/SLL IN THE DUO TRIAL

Age-related changes in eye morphology and aqueous humor dynamics in DBA/2J mice using contrast-enhanced ocular MRI

A HEAD‐TO‐HEAD PHASE 3 STUDY COMPARING BGB‐3111 AND IBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA

Suchergebnisse filtern